Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cullinan Therapeutics

8.94
+0.42004.93%
Volume:231.35K
Turnover:2.04M
Market Cap:523.10M
PE:-2.87
High:8.97
Open:8.56
Low:8.50
Close:8.52
Loading ...

Cullinan Therapeutics: Promising Developments and Strategic Growth in Autoimmune Therapies

TIPRANKS
·
19 Nov 2024

TD Cowen Keeps Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
18 Nov 2024

Cullinan Therapeutics to present preclinical data for CLN-978

TIPRANKS
·
14 Nov 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

GlobeNewswire
·
14 Nov 2024

Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)

TIPRANKS
·
11 Nov 2024

Stock Track | Cullinan Therapeutics Soars on Better-Than-Expected Q3 Earnings

Stock Track
·
09 Nov 2024

Cullinan Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

BRIEF-Cullinan Therapeutics Provides Corporate Update And Reports Q3 2024 Financial Results

Reuters
·
07 Nov 2024

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dow Jones
·
07 Nov 2024

BRIEF-Cullinan Oncology Q3 Net Income USD -40.56 Million

Reuters
·
07 Nov 2024

Cullinan Therapeutics Qtrly Share Loss $0.69

THOMSON REUTERS
·
07 Nov 2024

Cullinan Therapeutics Inc Q3 Shr View $-0.81 -- Lseg Ibes Data

THOMSON REUTERS
·
07 Nov 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

GlobeNewswire
·
05 Nov 2024

Cullinan Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview

Reuters
·
04 Nov 2024

Cullinan Therapeutics to present preclinical data for CLN-978

TIPRANKS
·
04 Nov 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

GlobeNewswire
·
04 Nov 2024